Boerner称BMS正将AI嵌入从发现到生产的整条价值链。
正如我们在之前的电话会上所说，AI对我们是重要的投资领域。我们着力思考如何在公司整个价值链中合理嵌入AI，从早期发现到商业化、生产以及几乎所有支持职能。原文 (en)
AI, as we have said on previous calls, is an important area and investment for us We are focused really on thinking about how we can embed AI where it makes sense across the entire value chain of the company, everything from early stage discovery through commercialization, manufacturing, and virtually all of our enabling functions.
Boerner称BMS已有8款增长组合药物年化销售额超10亿美元，增长基础广泛。
我们现在有8款增长组合药物，按第三季度销售额年化均超过10亿美元，为我们提供了广泛的增长驱动力。原文 (en)
We now have 8 growth portfolio medicines, each annualizing over $1 billion based on Q3 sales, giving us a broad base of growth drivers.
Boerner称积极的3期数据增强了对CELMoD和蛋白降解平台的信心，BMS处于领先地位。
这些结果进一步增强了我们对CELMoD及更广泛的靶向蛋白降解平台的信心，BMS在该领域是明确的领导者。原文 (en)
These results further strengthen our conviction in CELMoDs and our broader targeted protein degradation platform, where BMS is a clear leader.
Boerner重申业务拓展是首要资本配置优先事项，并将继续寻求外部创新。
正如我们一贯所说，业务拓展仍是首要资本配置优先事项。我们有很强的后期管线，但如果合适，我们始终会寻求外部创新。原文 (en)
BD continues, as we have said, consistently to be a top allocation priority. We have got a very strong late stage pipeline. But we are always gonna be looking for opportunities to source innovation externally if it makes sense for us to do so.
Boerner称Zolacel在自身免疫疾病中显示出潜在变革性活性，尽管暂停仍将继续推进。
关于Zolacel，我要说的是我们看到了潜在的变革性活性，我们很期待继续推进该项目。原文 (en)
what I will tell you with Zolacel specifically is we are seeing potentially transformational activity We are excited to continue this program.
Boerner认为小细胞肺癌患者将进一步细分，未来有多种药物并存的空间。
可能出现的情况是患者会继续被细分亚型，不仅在一线，在后续线治疗中也需要更多疗法，最终会有多种药物的空间。原文 (en)
what is likely to occur is you are going to see patients continue to be subtype. And additional therapies be required to treat patients not only in initial lines of therapy, but subsequent lines of therapy and I think at the end of the day, there is gonna be room for multiple agents to, be engaged to help treat these patients.